Nerve Growth Factor and Pain Mechanisms

Annual Review of Neuroscience

Volumn 40, Issue , 2017, Pages 307-325

  Denk, Franziska ^a   Bennett, David L ^b   McMahon, Stephen B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Chronic pain; Nerve growth factor; P75; TrkA

Indexed keywords

ANALGESIC AGENT; LIGAND; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR; PROTEIN INHIBITOR; NERVE GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE A;

ANALGESIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC PAIN; CLINICAL STUDY; HISTORICAL RESEARCH; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; NERVE ENDING; NERVE SPROUTING; NOCICEPTION; NOCICEPTIVE PAIN; NONHUMAN; PAIN RECEPTOR; PERIPHERAL NERVE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SENSITIZATION; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TRANSCRIPTION REGULATION; ANIMAL; METABOLISM; PAIN;

ANIMALS; CHRONIC PAIN; HUMANS; NERVE GROWTH FACTOR; PAIN; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA;

EID: 85027026364     PISSN: 0147006X     EISSN: 15454126     Source Type: Book Series    
DOI: 10.1146/annurev-neuro-072116-031121     Document Type: Article

References (126)

1. Aloe L, Mugnaini E, Levi-Montalcini R. 1975. Light and electron microscopic studies on the excessive growth of sympathetic ganglia in rats injected daily from birth with 6-OHDA and NGF. Arch. Ital. Biol. 113:326-53
2. Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R. 1992. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 35:351-55
3. Anand P. 2004. Neurotrophic factors and their receptors in human sensory neuropathies. Prog. Brain Res. 146:477-92
4. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. 1994. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 634:7-12
5. Barouch R, Kazimirsky G, Appel E, Brodie C. 2001. Nerve growth factor regulates TNF-production in mouse macrophages via MAP kinase activation. J. Leukoc. Biol. 69:1019-26
6. Barthel C, Yeremenko N, Jacobs R, Schmidt RE, Bernateck M, et al. 2009. Nerve growth factor and receptor expression in rheumatoid arthritis and spondyloarthritis. Arthritis Res. Ther. 11:R82
7. Basbaum AI, Bautista DM, Scherrer G, Julius D. 2009. Cellular and molecular mechanisms of pain. Cell 139:267-84
8. Bentley CA, Lee KF. 2000. p75 is important for axon growth and Schwann cellmigration during development. J. Neurosci. 20:7706-15
9. Bibel M, Hoppe E, Barde YA. 1999. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J. 18:616-22
10. Bonnington JK, Mc Naughton PA. 2003. Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor. J. Physiol. 551:433-46
11. Boutilier J, Ceni C, Pagdala PC, Forgie A, Neet KE, Barker PA. 2008. Proneurotrophins require endocytosis and intracellular proteolysis to induce Trk A activation. J. Biol. Chem. 283:12709-16
12. Bowman CJ, Evans M, Cummings T, Oneda S, Butt M, et al. 2015. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis). Reprod. Toxicol. 53:105-18
13. Bramson C, Herrmann DN, Carey W, Keller D, Brown MT, et al. 2015. Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 16:1163-76
14. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. 2006. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur. J. Pain 10:287-333
15. Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, et al. 2014. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J. Neurol. Sci. 345:139-47
16. Bueker ED. 1948. Implantation of tumors in the hind limb field of the embryonic chick and the developmental response of the lumbosacral nervous system. Anat. Rec. 102:369-89
17. Butt M, Evans M, Bowman CJ, Cummings T, Oneda S, et al. 2014. Morphologic, stereologic, andmorphometric evaluation of the nervous system in young cynomolgusmonkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor. Toxicol. Sci. 142:463-76
18. Calero-Nieto FJ, Ng FS, Wilson NK, Hannah R, Moignard V, et al. 2014. Key regulators control distinct transcriptional programmes in blood progenitor and mast cells. EMBO J. 33:1212-26
19. Cao E, Cordero-Morales JF, Liu B, Qin F, Julius D. 2013. TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids. Neuron 77:667-79
20. Cavazza A, Miccio A, Romano O, Petiti L, Malagoli Tagliazucchi G, et al. 2016. Dynamic transcriptional and epigenetic regulation of human epidermal keratinocyte differentiation. Stem Cell Rep. 6:618-32
21. Chao MV. 2003. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat. Rev. Neurosci. 4:299-309
22. Chao MV, Hempstead BL. 1995. p75 and Trk: A two-receptor system. Trends Neurosci. 18:321-26
23. Chen CY, Lee JB, Liu B, Ohta S, Wang PY, et al. 2015. Induction of interleukin-9-producing mucosal mast cells promotes susceptibility to Ig E-mediated experimental food allergy. Immunity 43:788-802
24. Chen W, Ye DY, Han DJ, Fu GQ, Zeng X, et al. 2016. Elevated level of nerve growth factor in the bladder pain syndrome/interstitial cystitis: A meta-analysis. Springer Plus 5:1072
25. Chisholm KA, Gilchrist JM. 2011. The Charcot joint: A modern neurologic perspective. J. Clin. Neuromuscul. Dis. 13:1-13
26. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, et al. 2001. Bradykinin and nerve growth factor release the capsaicin receptor from Ptd Ins(4, 5)P2-mediated inhibition. Nature 411:957-62
27. Cohen S. 1960. Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. PNAS 46:302-11
28. Davies AM. 1988. The emerging generality of the neurotrophic hypothesis. Trends Neurosci. 11:243-44
29. Davies AM. 1996. The neurotrophic hypothesis: Where does it stand. Philos. Trans. R. Soc. B 351:389-94
30. Dawes JM, Calvo M, Perkins J.R., Paterson KJ, Kiesewetter H, et al. 2011. CXCL5 mediates UVB irradiation-induced pain. Sci. Transl. Med. 3:90ra60
31. Denk F, Crow M, Didangelos A, Lopes DM, Mc Mahon SB. 2016. Persistent alterations in microglial enhancers in a model of chronic pain. Cell Rep. 15:1771-81
32. Di Castro A, Drew LJ, Wood JN, Cesare P. 2006. Modulation of sensory neuron mechanotransduction by PKC-A nd nerve growth factor-dependent pathways. PNAS 103:4699-704
33. di Mola FF, Friess H, Zhu ZW, Koliopanos A, Bley T, et al. 2000. Nerve growth factor and Trk high affinity receptor (Trk A) gene expression in inflammatory bowel disease. Gut 46:670-79
34. Dos Reis RC, Kopruszinski CM, Nones CF, Chichorro JG. 2016. Nerve growth factor induces facial heat hyperalgesia and plays a role in trigeminal neuropathic pain in rats. Behav. Pharmacol. 27:528-35
35. Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, et al. 2004. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum. Mol. Genet. 13:799-805
36. Farshchian M, Nissinen L, Siljamaki E, Riihila P, Toriseva M, et al. 2015. Eph B2 promotes progression of cutaneous squamous cell carcinoma. J. Investig. Dermatol. 135:1882-92
37. FDA (US Food Drug Admin.). 2012. Arthritis Advisory Committee (AAC) Meeting. Silver Spring, MD: US Food Drug Admin. http://www.fda.gov/downloads/Advisory Committees/Committees Meeting Materials/Drugs/Arthritis Advisory Committee/UCM307880.pdf
38. Flegel C, Schobel N, Altmuller J, Becker C, Tannapfel A, et al. 2015. RNA-seq analysis of human trigeminal and dorsal root ganglia with a focus on chemoreceptors. PLOS ONE 10:e0128951
39. Friess H, Zhu ZW, di Mola FF, Kulli C, Graber HU, et al. 1999. Nerve growth factor and its high-affinity receptor in chronic pancreatitis. Ann. Surg. 230:615-24
40. Fujimoto S, Uratsuji H, Saeki H, Kagami S, Tsunemi Y, et al. 2008. CCR4 and CCR10 are expressed on epidermal keratinocytes and are involved in cutaneous immune reaction. Cytokine 44:172-78
41. Ghilardi J.R., Freeman KT, Jimenez-Andrade JM, Coughlin KA, Kaczmarska MJ, et al. 2012. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum. 64:2223-32
42. Ginty DD, Segal RA. 2002. Retrograde neurotrophin signaling: Trk-ing along the axon. Curr. Opin. Neurobiol. 12:268-74
43. Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, et al. 2015. Osteoarthritis. Lancet 386:376-87
44. Gosselin D, Link VM, Romanoski CE, Fonseca GJ, Eichenfield DZ, et al. 2014. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 159:1327-40
45. Greene LA, Kaplan DR. 1995. Early events in neurotrophin signalling via Trk and p75 receptors. Curr. Opin. Neurobiol. 5:579-87
46. Harder AT, An YH. 2003. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: A concise review. J. Clin. Pharmacol. 43:807-15
47. Hempstead BL. 2006. Dissecting the diverse actions of pro-A nd mature neurotrophins. Curr. Alzheimer Res. 3:19-24
48. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. 1991. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350:678-83
49. Hochberg MC. 2015. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthr. Cartil. 23(Suppl. 1):S18-21
50. Howard L, Wyatt S, Nagappan G, Davies AM. 2013. Pro NGF promotes neurite growth from a subset of NGF-dependent neurons by a p75NTR-dependent mechanism. Development 140:2108-17
51. Hu G, Huang K, Hu Y, Du G, Xue Z, et al. 2016. Single-cell RNA-seq reveals distinct injury responses in different types of DRG sensory neurons. Sci. Rep. 6:31851
52. Hutchins AP, Takahashi Y, Miranda-Saavedra D. 2015. Genomic analysis of LPS-stimulated myeloid cells identifies a common pro-inflammatory response but divergent IL-10 anti-inflammatory responses. Sci. Rep. 5:9100
53. Iannone F, De Bari C, Dell'Accio F, Covelli M, Patella V, et al. 2002. Increased expression of nerve growth factor (NGF) and high affinity NGF receptor (p140 Trk A) in human osteoarthritic chondrocytes. Rheumatology 41:1413-18
54. Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, et al. 1996. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat. Genet. 13:485-88
55. Jimenez-Andrade JM, Ghilardi J.R., Castaneda-Corral G, Kuskowski MA, Mantyh PW. 2011. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain 152:2564-74
56. Jonas R, Klusch A, Schmelz M, Petersen M, Carr RW. 2015. Assessment of TTX-s and TTX-r action potential conduction along neurites of NGF and GDNF cultured porcine DRG somata. PLOS ONE 10:e0139107
57. Kanemaru K, Noguchi E, Tokunaga T, Nagai K, Hiroyama T, et al. 2015. Tie2 signaling enhances mast cell progenitor adhesion to vascular cell adhesion molecule-1 (VCAM-1) through 41 integrin. PLOS ONE 10:e0144436
58. Kelleher JH, Tewari D, Mc Mahon SB. 2016. Neurotrophic factors and their inhibitors in chronic pain treatment. Neurobiol. Dis. 97:127-38
59. Kivitz AJ, Gimbel JS, Bramson C, Nemeth MA, Keller DS, et al. 2013. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain 154:1009-21
60. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, et al. 2012. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8:445-544
61. Koltzenburg M, Bennett DLH, Shelton DL, Mc Mahon SB. 1999. Neutralization of endogenous NGF prevents the sensitization of nociceptors supplying inflamed skin. Eur. J. Neurosci. 11:1698-704
62. Lane LB, Villacin A, Bullough PG. 1977. The vascularity and remodelling of subchondrial bone and calcified cartilage in adult human femoral and humeral heads. An age-A nd stress-related phenomenon. J. Bone Joint Surg. Br. 59:272-78
63. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, et al. 2010. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363:1521-31
64. Larsson E, Kuma R, Norberg A, Minde J, Holmberg M. 2009. Nerve growth factor R221W responsible for insensitivity to pain is defectively processed and accumulates as pro NGF. Neurobiol. Dis. 33:221-28
65. Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, et al. 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159:1312-26
66. Lee R, Kermani P, Teng KK, Hempstead BL. 2001. Regulation of cell survival by secreted proneurotrophins. Science 294:1945-48
67. Leon A, Buriani A, Dal Toso R, Fabris M, Romanello S, et al. 1994. Mast cells synthesize, store, and release nerve growth factor. PNAS 91:3739-43
68. Levi-Montalcini R, Hamburger V. 1951. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 116:321-61
69. Lewin GR, Nykjaer A. 2014. Pro-neurotrophins, sortilin, and nociception. Eur. J. Neurosci. 39:363-74
70. Lewin GR, Rueff A, Mendell LM. 1994. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6:1903-12
71. Lindsay RM. 1988. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons. J. Neurosci. 8:2394-405
72. Malerba F, Paoletti F, Cattaneo A. 2016. NGF and pro NGF reciprocal interference in immunoassays: Open questions, criticalities, and ways forward. Front. Mol. Neurosci. 9:63
73. Mantyh PW. 2014. Bone cancer pain: From mechanism to therapy. Curr. Opin. Support. Palliat. Care 8:83-90
74. Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL. 2011. Antagonism of nerve growth factor-Trk A signaling and the relief of pain. Anesthesiology 115:189-204
75. Mardinly AR, Spiegel I, Patrizi A, Centofante E, Bazinet JE, et al. 2016. Sensory experience regulates cortical inhibition by inducing IGF1 in VIP neurons. Nature 531:371-75
76. Marmigere F, Ernfors P. 2007. Specification and connectivity of neuronal subtypes in the sensory lineage. Nat. Rev. Neurosci. 8:114-27
77. Mc Mahon SB, Armanini MP, Ling LH, Phillips HS. 1994. Expression and coexpression of Trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets. Neuron 12:1161-71
78. Mc Mahon SB, Bennett DLH, Priestley JV, Shelton DL. 1995. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trk A-Ig G fusion molecule. Nat. Med. 1:774-80
79. Meeker R, Williams K. 2014. Dynamic nature of the p75 neurotrophin receptor in response to injury and disease. J. Neuroimmune Pharmacol. 9:615-28
80. Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DLH, et al. 1997. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in Trk A-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17:8476-90
81. Minde J, Andersson T, Fulford M, Aguirre M, Nennesmo I, et al. 2009. A novel NGFB point mutation: A phenotype study of heterozygous patients. J. Neurol. Neurosurg. Psychiatry 80:188-95
82. Mitra R. 2013. The utilization of opiates in pain management: Use or abuse. Eur. J. Phys. Rehabil.Med. 49:93-96
83. Mizumura K, Murase S. 2015. Role of nerve growth factor in pain. Handb. Exp. Pharmacol. 227:57-77
84. Mo A, Mukamel EA, Davis FP, Luo C, Henry GL, et al. 2015. Epigenomic signatures of neuronal diversity in the mammalian brain. Neuron 86:1369-84
85. Mullard A. 2015. Drug developers reboot anti-NGF pain programmes. Nat. Rev. Drug Discov. 14:297-98
86. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, et al. 2004. Sortilin is essential for pro NGF-induced neuronal cell death. Nature 427:843-48
87. Omerbasic D, Smith ES, Moroni M, Homfeld J, Eigenbrod O, et al. 2016. Hypofunctional Trk A accounts for the absence of pain sensitization in the African naked mole-rat. Cell Rep. 17:748-58
88. Ostuni R, Piccolo V, Barozzi I, Polletti S, Termanini A, et al. 2013. Latent enhancers activated by stimulation in differentiated cells. Cell 152:157-71
89. Petersson ME, Obreja O, Lampert A, Carr RW, Schmelz M, Fransen E. 2014. Differential axonal conduction patterns of mechano-sensitive and mechano-insensitive nociceptors-a combined experimental and modelling study. PLOS ONE 9:e103556
90. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, et al. 1994. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann. Neurol. 36:244-46
91. Rajagopal R, Chen ZY, Lee FS, Chao MV. 2004. Transactivation of Trk neurotrophin receptors by G-proteincoupled receptor ligands occurs on intracellular membranes. J. Neurosci. 24:6650-58
92. Ramer MS, Thompson SW, Mc Mahon SB. 1999. Causes and consequences of sympathetic basket formation in dorsal root ganglia. Pain 82(Suppl. 1):S111-20
93. Reynders A, Mantilleri A, Malapert P, Rialle S, Nidelet S, et al. 2015. Transcriptional profiling of cutaneous MRGPRD free nerve endings and C-LTMRs. Cell Rep. 10:1007-19
94. Rinaldi L, Datta D, Serrat J, Morey L, Solanas G, et al. 2016. Dnmt3a and Dnmt3b associate with enhancers to regulate human epidermal stem cell homeostasis. Cell Stem Cell 19:491-501
95. Rueff A, Dawson AJ, Mendell LM. 1996. Characteristics of nerve growth factor induced hyperalgesia in adult rats: Dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activation. Pain 66:359-72
96. Rukwied R, Mayer A, Kluschina O, Obreja O, Schley M, Schmelz M. 2010. NGF induces non-inflammatory localized and lasting mechanical and thermal hypersensitivity in human skin. Pain 148:407-13
97. Sabsovich I, Wei T, Guo TZ, Zhao R, Shi X, et al. 2008. Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 138:47-60
98. Sanchez-Ortiz E, Yui D, Song D, Li Y, Rubenstein JL, et al. 2012. Trk A gene ablation in basal forebrain results in dysfunction of the cholinergic circuitry. J. Neurosci. 32:4065-79
99. Schnitzer TJ, Marks JA. 2015. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthr. Cartil. 23(Suppl. 1):S8-17
100. Sevcik MA, Ghilardi J.R., Peters CM, Lindsay TH, Halvorson KG, et al. 2005. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115:128-41
101. Shi Y, Mantuano E, Inoue G, Campana WM, Gonias SL. 2009. Ligand binding to LRP1 transactivates Trk receptors by a Src family kinase-dependent pathway. Sci. Signal. 2:ra18
102. Shu X, Mendell LM. 2001. Acute sensitization by NGF of the response of small-diameter sensory neurons to capsaicin. J. Neurophysiol. 86:2931-38
103. Skeldal S, Matusica D, Nykjaer A, Coulson EJ. 2011. Proteolytic processing of the p75 neurotrophin receptor: A prerequisite for signalling Neuronal life, growth and death signalling are crucially regulated by intramembrane proteolysis and trafficking of p75NTR. Bio Essays 33:614-25
104. Stachel SJ, Sanders JM, Henze DA, Rudd MT, Su HP, et al. 2014. Maximizing diversity from a kinase screen: Identification of novel and selective pan-Trk inhibitors for chronic pain. J. Med. Chem. 57:5800-16
105. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, Gordon SE. 2006. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J. Gen. Physiol. 128:509-22
106. Stucky CL, Koltzenburg M, Schneider M, Engle MG, Albers KM, Davis BM. 1999. Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. J. Neurosci. 19:8509-16
107. Thakur M, Crow M, Richards N, Davey GI, Levine E, et al. 2014. Defining the nociceptor transcriptome. Front. Mol. Neurosci. 7:87
108. Thakurela S, Garding A, Jung RB, Muller C, Goebbels S, et al. 2016. The transcriptome of mouse central nervous system myelin. Sci. Rep. 6:25828
109. Tigerholm J, Petersson ME, Obreja O, Lampert A, Carr R, et al. 2014. Modeling activity-dependent changes of axonal spike conduction in primary afferent C-nociceptors. J. Neurophysiol. 111:1721-35
110. Tomita K, Kubo T, Matsuda K, Fujiwara T, Yano K, et al. 2007. The neurotrophin receptor p75NTR in Schwann cells is implicated in remyelination and motor recovery after peripheral nerve injury. Glia 55:1199-208
111. Tomlinson RE, Li Z, Zhang Q, Goh BC, Li Z, et al. 2016. NGF-Trk A signaling by sensory nerves coordinates the vascularization and ossification of developing endochondral bone. Cell Rep. 16:2723-35
112. Tron VA, Coughlin MD, Jang DE, Stanisz J, Sauder DN. 1990. Expression and modulation of nerve growth factor in murine keratinocytes (PAM 212). J. Clin. Investig. 85:1085-89
113. Usoskin D, Furlan A, Islam S, Abdo H, Lonnerberg P, et al. 2015. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat. Neurosci. 18:145-53
114. Vaegter CB, Jansen P, Fjorback AW, Glerup S, Skeldal S, et al. 2011. Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat. Neurosci. 14:54-61
115. Verge VMK, Merlio JP, Grondin J, Ernfors P, Persson H, et al. 1992. Colocalization of NGF binding sites, trk m RNA, and low-affinity NGF receptor m RNA in primary sensory neurons: Responses to injury and infusion of NGF. J. Neurosci. 12:4011-22
116. Watanabe T, Ito T, Inoue G, Ohtori S, Kitajo K, et al. 2008. The p75 receptor is associated with inflammatory thermal hypersensitivity. J. Neurosci. Res. 86:3566-74
117. Wild KD, Bian D, Zhu D, Davis J, Bannon AW, et al. 2007. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J. Pharmacol. Exp. Ther. 322:282-87
118. Winter J, Forbes CA, Sternberg J, Lindsay RM. 1988. Nerve growth factor (NGF) regulates adult rat cultured dorsal root ganglion neuron responses to the excitotoxin capsaicin. Neuron 1:973-81
119. Woolf CJ. 1996. Phenotypic modification of primary sensory neurons: The role of nerve growth factor in the production of persistent pain. Philos. Trans. R. Soc. B 351:441-48
120. Woolf CJ, Ma QP, Allchorne A, Poole S. 1996. Peripheral cell types contributing to the hyperalgesic action of nerve growth factor in inflammation. J. Neurosci. 16:2716-23
121. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. 1994. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 62:327-31
122. Yune TY, Lee JY, Jung GY, Kim SJ, Jiang MH, et al. 2007. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 27:7751-61
123. Zahn PK, Subieta A, Park SS, Brennan TJ. 2004. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J. Pain 5:157-63
124. Zhang X, Huang J, Mc Naughton PA. 2005. NGF rapidly increases membrane expression of TRPV1 heatgated ion channels. EMBO J. 24:4211-23
125. Zhou FQ, Zhou J, Dedhar S, Wu YH, Snider WD. 2004. NGF-induced axon growth is mediated by localized inactivation of GSK-3 and functions of the microtubule plus end binding protein APC. Neuron 42:897-912
126. Zorbas M, Hurst S, Shelton D, Evans M, Finco D, Butt M. 2011. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul. Toxicol. Pharmacol. 59:334-42